Abstract
Meptazinol is a unique centrally active opioid analgesic, differing in many respects from the classical opiates or mixed antagonists. Although the overall binding of a series of 3H-labeled opioids is displaced poorly (IC50 values greater than 55 nM), detailed competition studies show that meptazinol inhibits a portion of 3H-labeled opiate and opioid peptide binding quite potently, with IC50 value under 1 nM. Both additional competition studies and saturation studies indicate that the meptazinol-sensitive binding of the 3H-ligands corresponds to the high affinity, or mu-1, binding site. In other binding studies meptazinol has a sodium shift of 8.7, midway between that of morphine (22.5) and naloxone (1.6), suggesting that it is a partial agonist. Naloxonazine treatment 24 hr earlier attenuates meptazinol analgesia in both the mouse writhing and rat tail-flick assays. Spinal transection in the mouse completely eliminates the analgesic activity of high doses of meptazinol in the tail-flick assay, implying a supraspinal mechanism of action in that species. Given at equianalgesic doses, morphine (3.5 mg/kg i.v.) significantly lowers the pO2 over 20 mm Hg and raises the pCO2 over 10 mm Hg as measured in arterial blood samples, whereas meptazinol (10 mg/kg i.v.) has no significant effects on either. Equally important, meptazinol administered with morphine does not reverse the respiratory depressant actions seen with morphine alone, distinguishing meptazinol from other mixed agonist/antagonists. Thus, both the binding and in vivo pharmacological studies are consistent with a mu-1 selective mechanism for the opioid actions of meptazinol.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|